1st Sep 2015 08:35
LONDON (Alliance News) - Allergy Therapeutics PLC on Tuesday said it has enrolled the first patient for its Pollinex Quattro Birch dose ranging study, which it will conduct in Germany and Austria.
The study will be conducted in approximately 25 centres across Germany and Austria, involving 350 patients. The product is a treatment for allergies to birch trees.
Allergy also reiterated it expects to post 11% constant currency revenue growth for the year.
Shares in Allergy were untraded on Tuesday, having last traded at 24.51 pence.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Allergy Thera.